middle.news
How Alterity’s ATH434 Slowed MSA Progression by 48% in Phase 2 Trials
4:07am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Alterity’s ATH434 Slowed MSA Progression by 48% in Phase 2 Trials
4:07am on Saturday 30th of August, 2025 AEST
Key Points
Net loss narrowed 36.5% to A$12.15 million
ATH434 Phase 2 trials show up to 48% slowing of MSA progression
FDA grants Fast Track designation for ATH434 in MSA
A$40 million capital raised, boosting cash reserves to over A$33 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE